{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:28:42Z","timestamp":1794965322636,"version":"4.9.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics, Inc.","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Little information is available regarding the burden of living with and managing epidermolysis bullosa, including the distinct challenges faced by patients with different disease types\/subtypes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A 90-question\/item survey was developed to collect demographics, diagnostic data, management practices, and burden of illness information for patients with epidermolysis bullosa living in the United States. Recruitment was conducted via email and social media in partnership with epidermolysis bullosa patient advocacy organizations in the United States, and the survey was conducted via telephone interview by a third-party health research firm. Respondents aged \u2265\u200918 years with a confirmed diagnosis of epidermolysis bullosa or caring for a patient with a confirmed diagnosis of epidermolysis bullosa were eligible to participate in the survey.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In total, 156 responses were received from patients (<jats:italic>n<\/jats:italic>\u2009=\u200963) and caregivers (<jats:italic>n<\/jats:italic>\u2009=\u200993) representing the epidermolysis bullosa types of simplex, junctional, and dystrophic (subtypes: dominant and recessive). A large proportion of patients (21%) and caregivers (32%) reported that the condition was severe or very severe, and 19% of patients and 26% of caregivers reported a visit to an emergency department in the 12\u2009months prior to the survey. Among the types\/subtypes represented, recessive dystrophic epidermolysis bullosa results in the greatest wound burden, with approximately 60% of patients and caregivers reporting wounds covering &gt;\u200930% of total body area. Wound care is time consuming and commonly requires significant caregiver assistance. Therapeutic options are urgently needed and reducing the number and severity of wounds was generally ranked as the most important treatment factor.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Survey responses demonstrate that epidermolysis bullosa places a considerable burden on patients, their caregivers, and their families. The limitations caused by epidermolysis bullosa mean that both patients and caregivers must make difficult choices and compromises regarding education, career, and home life. Finally, survey results indicate that epidermolysis bullosa negatively impacts quality of life and causes financial burden to patients and their families.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-019-1279-y","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T15:03:16Z","timestamp":1578063796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers"],"prefix":"10.1186","volume":"15","author":[{"given":"Anna L.","family":"Bruckner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Losow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson","family":"Wisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Reha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hjalmar","family":"Lagast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Gault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Gershkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Kopelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"1279_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1750-1172-9-76","volume":"9","author":"M El Hachem","year":"2014","unstructured":"El Hachem M, Zambruno G, Bourdon-Lanoy E, Ciasulli A, Buisson C, Hadj-Rabia S, et al. Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa. Orphanet J Rare Dis. 2014;9:76.","journal-title":"Orphanet J Rare Dis"},{"key":"1279_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-5-12","volume":"5","author":"JD Fine","year":"2010","unstructured":"Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010;5:12.","journal-title":"Orphanet J Rare Dis"},{"key":"1279_CR3","first-page":"288","volume":"69","author":"JE Ma","year":"2017","unstructured":"Ma JE, Hand JL. What's new with common genetic skin disorders? Minerva Pediatr. 2017;69:288\u201397.","journal-title":"Minerva Pediatr"},{"key":"1279_CR4","first-page":"36","volume":"10","author":"A Tabor","year":"2017","unstructured":"Tabor A, Pergolizzi JV Jr, Marti G, Harmon J, Cohen B, Lequang JA. Raising awareness among healthcare providers about epidermolysis bullosa and advancing toward a cure. J Clin Aesthet Dermatol. 2017;10:36\u201348.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1279_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","volume":"70","author":"JD Fine","year":"2014","unstructured":"Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70:1103\u201326.","journal-title":"J Am Acad Dermatol"},{"key":"1279_CR6","unstructured":"Debra International. Epidermolysis bullosa 2018. http:\/\/www.debra-international.org\/homepage.html. Accessed 9 Apr 2019."},{"key":"1279_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","volume":"152","author":"JD Fine","year":"2016","unstructured":"Fine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry. JAMA Dermatol. 2016;152:1231\u20138.","journal-title":"JAMA Dermatol"},{"key":"1279_CR8","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/jid.2013.127","volume":"133","author":"L Bruckner-Tuderman","year":"2013","unstructured":"Bruckner-Tuderman L, JA MG, Robinson EC, Uitto J. Progress in epidermolysis bullosa research: summary of DEBRA International research conference 2012. J Invest Dermatol. 2013;133:2121\u20136.","journal-title":"J Invest Dermatol"},{"key":"1279_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jid.2015.10.050","volume":"136","author":"J Uitto","year":"2016","unstructured":"Uitto J, Bruckner-Tuderman L, Christiano AM, JA MG, Has C, South AP, et al. Progress toward treatment and cure of epidermolysis bullosa: summary of the DEBRA International research symposium EB2015. J Invest Dermatol. 2016;136:352\u20138.","journal-title":"J Invest Dermatol"},{"key":"1279_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12916-014-0178-2","volume":"12","author":"KR Goldschneider","year":"2014","unstructured":"Goldschneider KR, Good J, Harrop E, Liossi C, Lynch-Jordan A, Martinez AE, et al. Pain care for patients with epidermolysis bullosa: best care practice guidelines. BMC Med. 2014;12:178.","journal-title":"BMC Med"},{"key":"1279_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/mgg3.315","volume":"5","author":"C von der Lippe","year":"2017","unstructured":"von der Lippe C, Diesen PS, Feragen KB. Living with a rare disorder: a systematic review of the qualitative literature. Mol Genet Genomic Med. 2017;5:758\u201373.","journal-title":"Mol Genet Genomic Med"},{"issue":"suppl 1","key":"1279_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10198-016-0783-4","volume":"17","author":"A Angelis","year":"2016","unstructured":"Angelis A, Kanavos P, Lopez-Bastida J, Linertova R, Oliva-Moreno J, Serrano-Aguilar P, et al. Social\/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Eur J Health Econ. 2016;17(suppl 1):31\u201342.","journal-title":"Eur J Health Econ"},{"key":"1279_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/erp.10.28","volume":"10","author":"C Pagliarello","year":"2010","unstructured":"Pagliarello C, Tabolli S. Factors affecting quality of life in epidermolysis bullosa. Expert Rev Pharmacoecon Outcomes Res. 2010;10:329\u201338.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1279_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijwd.2017.11.004","volume":"4","author":"SV Jain","year":"2018","unstructured":"Jain SV, Murrell DF. Psychosocial impact of inherited and autoimmune blistering diseases. Int J Womens Dermatol. 2018;4:49\u201353.","journal-title":"Int J Womens Dermatol"},{"key":"1279_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2340\/00015555-0947","volume":"90","author":"S Tabolli","year":"2010","unstructured":"Tabolli S, Pagliarello C, Uras C, Di Pietro C, Zambruno G, Castiglia D, et al. Family burden in epidermolysis bullosa is high independent of disease type\/subtype. Acta Derm Venereol. 2010;90:607\u201311.","journal-title":"Acta Derm Venereol"},{"key":"1279_CR16","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1365-2133.2009.09347.x","volume":"161","author":"JW Frew","year":"2009","unstructured":"Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol. 2009;161:1323\u201330.","journal-title":"Br J Dermatol"},{"key":"1279_CR17","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/bjd.16710","volume":"179","author":"H Dufresne","year":"2018","unstructured":"Dufresne H, Hadj-Rabia S, Bodemer C. Impact of a rare chronic genodermatosis on family daily life: the example of epidermolysis bullosa. Br J Dermatol. 2018;179:1177\u20138.","journal-title":"Br J Dermatol"},{"key":"1279_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-8-61","volume":"8","author":"P Davila-Seijo","year":"2013","unstructured":"Davila-Seijo P, Hernandez-Martin A, Morcillo-Makow E, de Lucas R, Dominguez E, Romero N, et al. Prioritization of therapy uncertainties in dystrophic Epidermolysis Bullosa: where should research direct to? An example of priority setting partnership in very rare disorders. Orphanet J Rare Dis. 2013;8:61.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1279-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1279-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1279-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:21:03Z","timestamp":1609546863000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1279-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1279"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1279-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The survey was approved by a central institutional review board (New England Independent Review Board). All patients or caregivers provided informed consent to participate in the survey.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ALB has served as a consultant and an investigator for Amicus Therapeutics\/Scioderm and Castle Creek, and as an investigator for Amryt, Fibrocell, ProQR, and Phoenix Tissue Repair.JW, NP, AR, HL, ML, and JGa, are employees of and hold stock in Amicus Therapeutics.JGe is the co-founder and vice chair on the board of Profession Patient Advocates in Life Sciences; a member of the board of trustees for the Healthcare Institute of New Jersey; a member of the board of directors for the Together Strong Foundation for NPC, and an employee of, and a stock holder and patent holder in, Amicus Therapeutics.BK is an employee of Debra of America.MH is an employee of EB Research Partnership.DFM has served as an investigator for Amicus Therapeutics, Amryt, Castle Creek, and Shire, and has served as an advisor for Amicus and Shire.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}